BioCryst Pharmaceuticals Inc Cash Flow Quality Index
BioCryst Pharmaceuticals Inc cash flow quality index. BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Quality Index of 0.76x as of December 2025. Operating cash flow of $276.04 Million is below net income of $362.26 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can BioCryst Pharmaceuticals Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BioCryst Pharmaceuticals Inc (2025–2025)
Cash flow quality index of BioCryst Pharmaceuticals Inc from 2025 to 2025. Historical Cash Flow Quality Index for BioCryst Pharmaceuticals Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. See how leveraged is BioCryst Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.
BioCryst Pharmaceuticals Inc Cash Flow Quality Index by Year (2025–2025)
BioCryst Pharmaceuticals Inc cash flow quality index by year from 2025 to 2025. Year-by-year earnings quality comparison for BioCryst Pharmaceuticals Inc. For the full cash flow conversion analysis, see BioCryst Pharmaceuticals Inc cash conversion from operations.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.25x | $329.88 Million | $263.86 Million | — |